MARKET

CORT

CORT

Corcept
NASDAQ

Real-time Quotes | Nasdaq Last Sale

17.57
-0.43
-2.37%
Opening 12:23 10/19 EDT
OPEN
18.20
PREV CLOSE
18.00
HIGH
18.20
LOW
17.46
VOLUME
206.79K
TURNOVER
--
52 WEEK HIGH
23.48
52 WEEK LOW
9.70
MARKET CAP
2.03B
P/E (TTM)
18.87
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Here's Why I Think Corcept Therapeutics (NASDAQ:CORT) Is An Interesting Stock
It's only natural that many investors, especially those who are new to the game, prefer to buy shares in 'sexy' stocks...
Simply Wall St. · 3d ago
Revisiting Corcept Therapeutics
Today, we revisit Corcept Therapeutics, a name we have not looked at in depth in some time.The company has one primary product on the market and a couple of 'shots on goal' in its pipeline.A full investment analysis follows in the paragraphs below.
Seekingalpha · 6d ago
Hedge Funds Have Never Been This Bullish On Corcept Therapeutics Incorporated (CORT)
How do you pick the next stock to invest in? One way would be to spend days of research browsing through thousands of publicly traded companies. However, an easier way is to look at the stocks that smart money investors are collectively bullish on. Hedge funds and other institutional investors usually
Insider Monkey · 10/05 16:46
Corcept Therapeutics Incorporated's (NASDAQ:CORT) Shares Climb 26% But Its Business Is Yet to Catch Up
Corcept Therapeutics Incorporated (NASDAQ:CORT) shareholders would be excited to see that the share price has had a...
Simply Wall St. · 09/18 12:26
Corcept's Lead Drug Korlym Aids Growth, Heavy Reliance a Woe
Corcept's (CORT) Cushing's syndrome drug Korlym shows a steady progress. Other pipeline candidates are advancing as well. However, heavy dependence on Korlym for growth remains an overhang.
Zacks · 09/17 14:56
Corcept Therapeutics Initiates Second Phase 2 Trial of Miricorilant to Treat Weight Gain Caused by Antipsychotic Medication
MENLO PARK, Calif., Sept. 10, 2020 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of cortisol, today announced enrollment
GlobeNewswire · 09/10 12:30
BiohavenPharmaHldg Reaches 80-Plus Relative Strength Rating Benchmark
Investor's Business Daily · 09/08 08:34
Stocks To Watch: Arena Pharmaceuticals Sees Relative Strength Rating Rise To 83
Investor's Business Daily · 09/04 15:41
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of CORT. Analyze the recent business situations of Corcept through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 4 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average CORT stock price target is 17.75 with a high estimate of 26.00 and a low estimate of 7.00.
EPS
Institutional Holdings
Institutions: 304
Institutional Holdings: 108.32M
% Owned: 93.74%
Shares Outstanding: 115.56M
TypeInstitutionsShares
Increased
72
4.30M
New
70
500.63K
Decreased
66
3.89M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
-0.44%
Pharmaceuticals & Medical Research
-0.52%
Key Executives
Chairman/Director/Independent Director
James Wilson
President/Chief Executive Officer/Director
Joseph Belanoff
Chief Financial Officer/Secretary
Gary Robb
Senior Vice President
Sean Maduck
Independent Director
G. Leonard Baker
Chief Accounting Officer
J.D. Lyon
Independent Director
G.Leonard Baker
Other
Andreas Grauer
Independent Director
Gregg Alton
Independent Director
George Baker
Independent Director
David Mahoney
Independent Director
Kimberly Park
Independent Director
Daniel Swisher
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About CORT
Corcept Therapeutics Incorporated is a pharmaceutical company engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic, psychiatric and oncologic disorders. The Company is developing mifepristone, a compound that modulates the effects of cortisol by acting as a competitive antagonist at the glucocorticoid receptor (GR). As of December 31, 2016, it had discovered three structurally distinct series of selective cortisol modulators, all of which share mifepristone's affinity for GR but, unlike mifepristone, do not bind to the progesterone receptor. It is conducting two clinical trials of its selective cortisol modulator, CORT125134. One trial is investigating CORT125134 as a treatment for patients with Cushing syndrome. The second trial is investigating the combination of CORT125134 and nab-paclitaxel (Celgene Corporation's Abraxane) to treat patients with solid-tumor cancers.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Corcept Therapeutics Incorporated stock information, including NASDAQ:CORT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CORT stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CORT stock methods without spending real money on the virtual paper trading platform.